The ready-to-use kits provide broad serotype coverage, standardized reagents, and simplified workflows for laboratories measuring adeno-associated virus capsids.
Abselion has launched two new adeno-associated virus (AAV) quantification kits designed to streamline total capsid quantification for gene therapy researchers and clinical laboratories.
The Cambridge, UK-based life sciences technology company introduced the AAVX Total Capsid Quantification Kit and the AAV9 Total Capsid Quantification Kit, both designed for use with its Amperia benchtop quantification platform. The kits incorporate Thermo Fisher Scientific’s CaptureSelect affinity reagents under a licensing agreement between the two companies.
The AAVX kit provides broad serotype coverage including AAV1-8 and AAVrh10, while the AAV9 kit focuses specifically on AAV9 particle quantification. Both products use a sandwich-style immunoassay format with biotin- and HRP-conjugated CaptureSelect antibodies that sequentially bind AAV capsids, with results detected electrochemically using Amperia sensor strips.
Ready-to-Use Format Reduces Optimization Requirements
Each kit comes in a ready-to-use format that includes sensor strips, assay plates, matched detection reagents, and assay buffers for binding and detection steps. The standardized format aims to reduce the need for in-house optimization that laboratories typically require when developing AAV quantification assays.
The Amperia platform operates without optics, fluidics, or specialized training requirements, positioning it as an accessible solution for laboratories that may lack extensive instrumentation or technical expertise in AAV quantification.
“Reliable quantification of total AAV capsid concentration is key to maintaining consistency and supporting informed decision-making,” says Dr Ruizhi Wang, CEO and founder of Abselion, in a release. “The integration of Thermo Fisher Scientific’s CaptureSelect reagents strengthens the performance of Abselion’s AAV kits and reflects our focus on making high-quality titre measurement simpler and more accessible.”
CaptureSelect Technology Integration
The licensing agreement allows Abselion to incorporate CaptureSelect technology, which is based on recombinant single-domain antibodies designed for high target specificity, low cross-reactivity, and consistent batch performance. These characteristics are intended to ensure reproducible titre quantification across different sample types and concentrations.
“CaptureSelect affinity reagents are designed to deliver high specificity and lot-to-lot consistency, making them well suited for applications such as AAV capsid quantification,” says Dr Kelly Flook, senior manager of product management for pharma analytics at Thermo Fisher Scientific, in a release.
The kits are designed to work with both purified and complex samples, potentially expanding their utility across different stages of gene therapy development and manufacturing workflows. This capability could benefit clinical laboratories involved in gene therapy testing and quality control processes.
The expanded kit portfolio enhances the utility of the Amperia platform for scientists working across gene therapy development and process workflows, offering laboratories a standardized approach to AAV quantification that could improve consistency and reduce method development time.
Photo caption: Adeno-associated virus quantification kit
Photo credit: Abselion
